Oragenics (NYSEAMERICAN:OGEN) Stock Passes Above 200-Day Moving Average of $0.00
Oragenics (NYSEAMERICAN:OGEN) Stock Passes Above 200-Day Moving Average of $0.00
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.00 and traded as high as $3.58. Oragenics shares last traded at $3.37, with a volume of 7,412 shares.
在週二的交易中，Oragenics, Inc.（紐約證券交易所美國證券交易所代碼：OGEN — Get Rating）的股價突破了其兩百天移動平均線。該股的兩百天移動平均線爲0.00美元，交易價格高達3.58美元。Oragenics股票最後一次交易價格爲3.37美元，成交量爲7,412股。
Oragenics Price Performance
Oragenics 價格表現
The firm has a market capitalization of $6.60 million, a P/E ratio of -25.92 and a beta of 0.19.
該公司的市值爲660萬美元，市盈率爲-25.92，beta值爲0.19。
Institutional Inflows and Outflows
機構流入和流出
Hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in shares of Oragenics by 116.5% during the 2nd quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company's stock worth $73,000 after acquiring an additional 112,800 shares during the period. Millennium Management LLC grew its holdings in shares of Oragenics by 591.6% during the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 110,119 shares during the period. Finally, State Street Corp grew its holdings in shares of Oragenics by 8.1% during the 1st quarter. State Street Corp now owns 495,563 shares of the biotechnology company's stock worth $171,000 after acquiring an additional 37,338 shares during the period. Hedge funds and other institutional investors own 9.31% of the company's stock.
對沖基金最近買入和賣出了該公司的股票。Renaissance Technologies LLC在第二季度將其持有的Oragenics的股票增加了116.5％。Renaissance Technologies LLC在此期間又收購了11,800股股票後，現在擁有這家生物技術公司的209,600股股票，價值73,000美元。千禧管理有限責任公司在第二季度將其持有的Oragenics的股票增加了591.6％。Millennium Management LLC在此期間又收購了110,119股股票後，現在擁有這家生物技術公司的128,733股股票，價值45,000美元。最後，State Street Corp在第一季度將其持有的Oragenics的股票增加了8.1％。State Street Corp在此期間又收購了37,338股股票後，現在擁有這家生物技術公司的495,563股股票，價值17.1萬美元。對沖基金和其他機構投資者擁有該公司9.31％的股票。
Oragenics Company Profile
Oragenics 公司簡介
(Get Rating)
（獲取評分）
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Oragenics, Inc在美國開發用於傳染病的抗生素。該公司參與NT-CoV-2-1（一種提供新型嚴重急性呼吸綜合徵冠狀病毒免疫力的鼻內候選疫苗）的開發和商業化；以及提供對新型嚴重急性呼吸綜合徵冠狀病毒免疫的肌肉注射候選疫苗Terra CoV-2。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Weight Watchers Reshapes Itself with a Game-Changer Acquisition
- Two Tiny Mining Stocks Worth Considering for the Next Gold Rush
- Nano Dimension Prints Growth: Enters Hypergrowth Phase
- CF Is Set To Harvest The Bull Run In Agricultural Stocks
- Oracle Dips But The Trend Is Strong
- 免費獲取 StockNews.com 關於 Oragenics (OGEN) 的研究報告
- Weight Watchers 通過收購改變遊戲規則的方式重塑自我
- 下一次淘金熱值得考慮的兩隻小型礦業股
- Nano Dimension 打印成長：進入超生長階段
- CF 將收穫農業股的牛市
- 甲骨文下跌但趨勢強勁
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oragenics Daily 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Oragenics及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。